TABLE 1.
MONOCYTE CHEMOATTRACTANT PROTEIN–1(CCL2) BLOCKADE DOES NOT CHANGE RECRUITMENT OF IMMUNOCYTES INTO THE TUMOR
| Cell Type | Flow Marker | Control* | α-CCL2* | P Value |
|---|---|---|---|---|
| Leukocytes | CD45+ | 6.4 ± 0.4% | 6.5% ± 0.7% | NS |
| Tumor-associated macrophages | CD11b+ Ly6G− | 4.7 ± 0.3% | 4.7% ± 0.4% | NS |
| Neutrophils (TAN) | CD11b+ Ly6G+ | 0.16 ± 0.03% | 0.39% ± 0.1% | <0.05 |
| T-cytotoxic | CD8+ | 0.52 ± 0.07% | 0.45% ± 0.04% | NS |
| T-helper | CD4+ | 0.38 ± 0.18% | 0.39% ± 0.19% | NS |
| Dendritic cells | CD11c+ | 1.4 ± 0.4% | 1.1% ± 0.1% | NS |
Definition of abbreviation: NS, no significance.
Data are expressed as percentages of total tumor cells.
Mice (n = 7–15 for each marker) bearing large tissue culture 1 tumors (approximately 200 mm3) were treated with either saline (control) or intraperitoneal α-CCL2 monoclonal antibody. When tumor volume curves started to diverge, tumors were harvested, digested, and subjected to flow cytometry. The percentage of different cells in each group was calculated. No significant differences were evident in the percentage of different immune cells in the tumors, except for a small but significant change in the percentage of intratumoral neutrophils.